Search

Search Constraints

You searched for: Author/Creator Dietrich, Daniel

Search Results

1. A systematic review and meta-analysis comparing surgical and oncological outcomes of upper rectal, rectosigmoid and sigmoid tumours. Issue 9 (September 2021)

2. Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies. (June 2021)

3. Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. Issue 2 (March 2019)

4. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. (August 2018)

5. Corrigendum to "Critique of the "Comment" etitled "Pyrethroid exposure: not so harmless after all" by Demeneix et al. (2020) published in the lancet diabetes endocrinology". (1st August 2021)

6. Critique of the "Comment" etitled "Pyrethroid exposure: Not so harmless after all" by Demeneix et al. (2020) published in the lancet diabetes endocrinology. (1st April 2021)

7. Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. (1st August 2020)

8. Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. (1st October 2020)

9. Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. (August 2020)

10. Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Issue 13 (17th July 2020)